Answers are grounded in this paper and cite their sources.
Meta-analysis shows EVT improves survival and function beyond 90 days in stroke, indicating sustained benefit.
Objective: We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of endovascular thrombectomy (EVT) beyond 90 days in patients of acute ischemic stroke (AIS) with large vessel occlusion (LVO). Background: EVT improves functional outcomes in patients of acute ischemic stroke at 90 days. However, its long-term efficacy and safety beyond 90 days remain uncertain. Design/Methods: PubMed, Embase, Scopus, and Cochrane Central databases were searched to identify randomized controlled trials (RCTs) comparing EVT plus medical therapy (MT) versus MT alone in AIS patients with LVO. Primary outcomes included functional independence (mRS ≤2), independent ambulation (mRS ≤3), death or dependency (mRS 4–6) and all-cause mortality beyond 90 days. We applied a random effects model and pooled risk ratios (RRs) along with 95% confidence interval (CI) using RevMan 5.4. Quality assessment was performed using the Rob2 tool. Results: Six RCTs with 1,856 patients (57% males) were included. The mean age of the patients was 68.9 years and mean follow up duration was 1.08 years. The results showed that EVT combined with MT improved functional independence (mRS ≤2) (RR 2.41, CI: 1.52–3.83; P = 0.0002), independent ambulation (mRS ≤3) (RR 1.76, CI: 1.31–2.37; P = 0.0002), and quality of life (SMD 0.43; CI: 0.26–0.59; P < 0.00001) beyond 90-days compared to MT alone. Moreover, the EVT plus MT group also had a significantly reduced death or dependency (mRS 4–6) (RR 0.77, CI: 0.71–0.83; P < 0.00001) and all-cause mortality (RR 0.86, CI: 0.77–0.96; P = 0.005) beyond 90-days than MT group. All RCTs were rated as low risk of bias. Conclusions: EVT combined with medical treatment significantly improves long-term functional outcomes and quality of life as well as reduces mortality in AIS patients with LVO than medical treatment alone. Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff. Disclosure: Dr. Osama has nothing to disclose. Mr. Shahid has nothing to disclose. Dr. Ali has nothing to disclose. Dr. Qasim has nothing to disclose. Dr. Joshi has received personal compensation for serving as an employee of Essen Healthcare. Dr. Joshi has received personal compensation for serving as an employee of CityMD. Dr. Joshi has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for SGS Consulting. Dr. Faheem has nothing to disclose.
No takes yet. Share an insight, caveat, or question.
Osama et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: